HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive, trastuzumab-refractory metastatic breast

被引：0
|
作者：
Han, S.
Ro, J.
Paquet, A.
Huang, W.
Weidler, J.
Lee, K. S.
Park, I.
Oh, D.
Im, S.
Kim, T.
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[2] Natl Canc Ctr, Goyang Si, South Korea
[3] Monogram Biosci Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1088
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
    Han, Sae-Won
    Cha, Yongjun
    Paquet, Agnes
    Huang, Weidong
    Weidler, Jodi
    Lie, Yolanda
    Sherwood, Thomas
    Bates, Michael
    Haddad, Mojgan
    Park, In Hae
    Oh, Do-Youn
    Lee, Keun Seok
    Im, Seock-Ah
    Bang, Yung-Jue
    Ro, Jungsil
    Kim, Tae-You
    PLOS ONE, 2012, 7 (07):
  • [2] Correlation between HER2 related biomarkers (HER2, p95HER2, HER3, PTEN and PIK3CA) and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer refractory to trastuzumab.
    Nishimura, Reiki
    Toh, Uhi
    Tanaka, Maki
    Saimura, Michiyo
    Okumura, Yasuhiro
    Saito, Tsuyoshi
    Tanaka, Toshihiro
    Teraoka, Megumi
    Shimada, Kazuo
    Katayama, Kazuhisa
    Koga, Toshihiro
    Kurashita, Kaname
    Hasegawa, Satoshi
    Todoroki, Hidekazu
    Ueo, Hiroaki
    Arima, Nobuyuki
    Mitsuyama, Shoshu
    Tamura, Kazuo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab
    Nishimura, Reiki
    Toh, Uhi
    Tanaka, Maki
    Saimura, Michiyo
    Okumura, Yasuhiro
    Saito, Tsuyoshi
    Tanaka, Toshihiro
    Teraoka, Megumi
    Shimada, Kazuo
    Katayama, Kazuhisa
    Koga, Toshihiro
    Kurashita, Kaname
    Hasegawa, Satoshi
    Todoroki, Hidekazu
    Kai, Yuichiro
    Ohi, Yasuyo
    Toyoshima, Satoshi
    Arima, Nobuyuki
    Mitsuyama, Shoshu
    Tamura, Kazuo
    ONCOLOGY, 2017, 93 (01) : 51 - 61
  • [4] HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
    Allan Lipton
    Laurie Goodman
    Kim Leitzel
    Jennifer Cook
    Jeff Sperinde
    Mojgan Haddad
    Wolfgang J. Köstler
    Weidong Huang
    Jodi M. Weidler
    Suhail Ali
    Alicia Newton
    Eva-Marie Fuchs
    Agnes Paquet
    Christian F. Singer
    Reinhard Horvat
    Xueguang Jin
    Joyee Banerjee
    Ali Mukherjee
    Yuping Tan
    Yining Shi
    Ahmed Chenna
    Jeff Larson
    Yolanda Lie
    Thomas Sherwood
    Christos J. Petropoulos
    Stephen Williams
    John Winslow
    Gordon Parry
    Michael Bates
    Breast Cancer Research and Treatment, 2013, 141 : 43 - 53
  • [5] HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
    Lipton, Allan
    Goodman, Laurie
    Leitzel, Kim
    Cook, Jennifer
    Sperinde, Jeff
    Haddad, Mojgan
    Koestler, Wolfgang J.
    Huang, Weidong
    Weidler, Jodi M.
    Ali, Suhail
    Newton, Alicia
    Fuchs, Eva-Marie
    Paquet, Agnes
    Singer, Christian F.
    Horvat, Reinhard
    Jin, Xueguang
    Banerjee, Joyee
    Mukherjee, Ali
    Tan, Yuping
    Shi, Yining
    Chenna, Ahmed
    Larson, Jeff
    Lie, Yolanda
    Sherwood, Thomas
    Petropoulos, Christos J.
    Williams, Stephen
    Winslow, John
    Parry, Gordon
    Bates, Michael
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 141 (01) : 43 - 53
  • [6] Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
    Duchnowska, Renata
    Sperinde, Jeff
    Czartoryska-Arlukowicz, Bogumila
    Mysliwiec, Paulina
    Winslow, John
    Radecka, Barbara
    Petropoulos, Christos
    Demlova, Regina
    Orlikowska, Marlena
    Kowalczyk, Anna
    Lang, Istvan
    Ziolkowska, Barbara
    Debska-Szmich, Sylwia
    Merdalska, Monika
    Grela-Wojewoda, Aleksandra
    Zawrocki, Anton
    Biernat, Wojciech
    Huang, Weidong
    Jassem, Jacek
    ONCOTARGET, 2017, 8 (61) : 104149 - 104159
  • [7] P95HER2 Expression in HER2-Positive Breast Cancer
    Goh, Chih Wan
    Zhang, Liyi
    Chi, Wei-Ru
    Xiu, Bingqiu
    Chen, Jiajian
    Yang, Wenqing
    Ao, Chunxia
    Tang, Jianxing
    Xue, Jingyan
    Chi, Yayun
    Wu, Jiong
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Quantitative p95HER2 protein expression is predictive of trastuzumab response in HER2-positive metastatic breast cancer
    Sperinde, J.
    Bachmeier, B.
    Weidler, J. M.
    Lie, Y.
    Chenna, A.
    Winslow, J.
    Engel, J.
    Schubert-Fritschle, G.
    Sommerhoff, C.
    Petropoulos, C.
    Bates, M.
    Huang, W.
    Nerlich, A.
    CANCER RESEARCH, 2016, 76
  • [9] Correlation of quantitative p95HER2, HER2, and HER3 protein expression with pathologic complete response (pCR) in HER2-positive breast cancer patients (pts) treated with neoadjuvant chemotherapy and trastuzumab
    Villasboas, Jose Caetano
    Hurley, Judith
    Weidler, Jodi Marie
    Paquet, Agnes
    Fernandez, Carmen Gomez
    Lavina, Maureen Cioffi
    Sperinde, Jeff
    Chenna, Ahmed
    Haddad, Mojgan
    Lie, Yolanda
    Winslow, John William
    Huang, Weidong
    Petropoulos, Christos J.
    Pegram, Mark D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [10] p95HER2 expression in HER2-positive breast cancer with primary resistance
    Goh, Chih Wan
    Yang, Benlong
    Chi, Yayun
    Wu, Jiong
    PRECISION MEDICAL SCIENCES, 2024, 13 (02): : 99 - 106
12345